Buparvaquone Nanostructured Lipid Carrier: Development of an Affordable Delivery System for the Treatment of Leishmaniases

Table 7

Observed and predicted -average, polydispersity index (PDI), and zeta potential (ZP) results from buparvaquone nanostructured lipid carriers.

	Observed -average (nm) ± RSD (%)	Predicted -average (nm) (α = 0.05)	PDI ± RSD (%)	ZP (mV) ± RSD (%)
F1	215.4 ± 1.7	183.8 to 217.4	0.152 ± 7.6	−20.3 ± 4.7
F2	231.2 ± 1.0	200.8 to 232.4	0.136 ± 4.9	−20.9 ± 1.0

F1: SL : LL: 0.71, Tween 80: 0.37% (w/w), and Kolliphor P188: 3.63% (w/w); F2: SL : LL: 2.06, Tween 80: 0.37% (w/w), and Kolliphor P188: 3.63% (w/w).